Comparison 7. Gluco+IFN versus Control+IFN (low and high dose IFN) at maximal follow‐up.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Loss of HBeAg	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [1.03, 1.92]
1.1 Low dose IFN	4	170	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.32 [0.66, 2.65]
1.2 High dose IFN	9	620	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.43 [1.01, 2.02]
2 HBeAg to anti‐HBe seroconversion	8	554	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.26 [0.87, 1.82]
2.1 Low dose IFN	2	124	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.14 [0.47, 2.76]
2.2 High dose IFN	6	430	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.29 [0.86, 1.93]
3 Loss of HBsAg	11	705	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.77, 2.59]
3.1 Low dose IFN	3	161	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.30 [0.56, 19.36]
3.2 High dose IFN	8	544	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.26 [0.66, 2.40]
4 Loss of HBV DNA	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.51 [1.12, 2.05]
4.1 Low dose IFN	4	170	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.49 [0.75, 2.96]
4.2 High dose IFN	9	620	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.52 [1.08, 2.14]
5 Normalisation of ALT or AST activities	9	583	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.12 [0.78, 1.62]
5.1 Low dose IFN	3	106	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.91 [0.40, 2.06]
5.2 High dose IFN	6	477	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.18 [0.79, 1.78]